Colorectal LLM Wiki

Browse
Home / Sources / ASCRS Ch53 - Radiation, Microscopic, and Ischemic Colitis
Source created 2026-08-25 · updated 2026-08-25
colorectalradiation-colitismicroscopic-colitisischemic-colitistextbook

ASCRS Ch53 - Radiation, Microscopic, and Ischemic Colitis

Fifty-third chapter of the ASCRS Textbook of Colon and Rectal Surgery, 4th edition (Cannon JA, Kennedy GD). Book pages 893–905 (PDF pages 884–896 of raw/ASCRS Textbook 4th Ed.pdf, offset +9 — one higher than Ch52's +8, confirmed by printed folio; another blank unnumbered page apparently falls between Ch52 and Ch53). A three-condition survey chapter, unusually trial-rich throughout (unlike Ch51's breadth-over-depth style) — most claims in all three sections are backed by specific named studies with quantified results rather than generic textbook narrative.

Key concepts (chapter's own summary box)

  • Radiation injury to the colon and rectum can cause significant morbidity, with effects seen many years after initial exposure.
  • Surgery should be a last resort for radiation injury given frequent complications; treatment should be individualized based on symptoms and clinical context.
  • Microscopic colitis is a rare cause of non-bloody diarrhea characterized by nonspecific inflammation in the lamina propria with lymphocyte/plasma cell infiltrates.
  • Budesonide is the only evidence-based treatment of microscopic colitis.
  • Ischemic colitis results from disruption of blood flow from small vessels and is distinct from mesenteric ischemia; treatment is based on symptom management and patient optimization.
  • Long-term complications of ischemic colitis include strictures and chronic ischemia, which may be indications for elective surgery in an otherwise medically optimized patient.

Filing

Three condition pages touched, one newly created:

  • Radiation colitis/proctitis → new page Radiation Colitis (Proctitis) — deliberately kept separate from the existing Radiation Enteritis (Sabiston-sourced, small-bowel-focused). The two conditions share an underlying radiation-vasculopathy mechanism and some medical management overlap, but the colorectal-specific presentation (hemorrhagic proctitis) and its endoscopic therapies (formalin, argon beam coagulation) are distinct enough — and detailed enough in this chapter — to warrant their own page rather than merging into the small-bowel page. Cross-linked both directions.
  • Microscopic colitis → new page Microscopic Colitis — no prior wiki page existed for this condition at all.
  • Ischemic colitis → substantial reconciliation of the existing, already-detailed Ischemic Colitis page (Sabiston-sourced). This chapter adds quantified epidemiology by patient subgroup, the pathognomonic "ghost cells" histologic finding, LGIB-etiology proportion data, a CT-accuracy study, and named surgical-outcome studies — genuine additions rather than duplication of the existing watershed-anatomy/risk-factor/endoscopy content.

Radiation colitis — chapter detail

Acute (during/within 6 months of therapy) vs. chronic (persisting beyond 6 months, or new-onset after a latent period, most commonly 8–12 months post-treatment) forms. ~400,000 patients annually receive pelvic radiation (anal, cervical, prostate, rectal, less often bladder/endometrial cancers). Acute symptoms in 50–75% of patients from cell loss in rapidly turning over rectal mucosa; resolves as turnover replaces damaged epithelium. Chronic radiation colitis does not improve over time — hemorrhagic proctitis (the most common chronic manifestation, from microvascular ischemia/fibrosis) has been diagnosed as late as 30 years post-treatment. RTOG toxicity grading table (Grade 1: mild symptoms not requiring meds; Grade 4: obstruction/fistula/perforation/transfusion-requiring bleeding) distinguishes acute from late scoring.

Dose relationship: incidence historically as high as 30%, now 1–5% with modern delivery (IMRT/VMAT, CT-based planning). Doses <45 Gy rarely cause chronic colitis; >70 Gy causes significant injury. Standard rectal cancer chemoradiation (45–54 Gy) carries lower risk than cervical cancer treatment (45–50 Gy external beam + brachytherapy escalation to 90 Gy focally) — rectovaginal fistulas most often follow cervical cancer treatment, rectourethral fistulas follow prostate treatment; both are unusual after standard rectal cancer treatment. Risk factors beyond dose: preexisting IBD, diabetes/hypertension/nicotine/PVD/adjuvant chemo/previous surgery (vascular-injury predisposition).

Prevention: positioning/full-bladder techniques, IMRT/VMAT, titanium clip-guided targeting. Pharmacologic prevention agents (sucralfate, short-chain fatty acids, probiotics) studied without clear benefit; glutamine enemas showed mixed results across two RCTs (Nascimento positive, Vidal-Casriego negative); amifostine (oxygen free-radical scavenger) is the most promising agent but not used routinely. Surgical prevention (mesh/omentum to exclude small bowel from pelvis) has not been shown to reduce incidence.

Diagnosis: no specific labs; clinical history + endoscopic appearance (pallor, telangiectasias, easy friability) are the mainstays. Biopsy only if diagnosis is in question — biopsies increase fistula risk and are otherwise unnecessary.

Medical management (mucosal protection/anti-inflammatory): sucralfate enemas have the best supporting data (Kochhar: 77% improved at 1 month, 92% at 4 months with twice-daily enemas) but practical burden limits use; metronidazole shown effective in two studies though no durable regimen established; antioxidant vitamins (A/E/C) show small-study benefit; mesalamine/ASA/steroids lack sufficient data. Hyperbaric oxygen effective (Oscarsson: 89% success in 39 patients) but requires 36–40 treatments — a considerable time/cost burden that has made endoscopic therapy the preferred route.

Endoscopic therapy — the chapter's preferred management for hemorrhagic radiation proctitis:

  • Topical formalin — the authors' first-choice therapy given ease of use, availability, excellent success, and low complication rate. Multiple administration techniques described: Sharma (50mL 4% formalin sprayed via flexible sigmoidoscope, 3-minute contact, repeated 3×; 29 patients, 96% complete/partial bleeding response, no complications); Raman (100cc 2% formalin enema, 24 patients, 48% complete + 30% partial response); Haas (10% formalin on a cotton-tipped applicator held 60 seconds, 100 patients, 93% success — one of the largest series). Luna-Perez reported a 20% severe-complication rate as a cautionary outlier, but the vast majority of studies show excellent safety. Perianal skin protection (lidocaine jelly) is important given formalin's causticity.
  • Argon beam coagulation (ABC) — similar effectiveness to formalin (Sebastian: 81% complete bleeding cessation in 25 patients; Zinicola: 86% success), with more uniform/predictable penetration depth (1–3mm) than formalin. Yeoh's direct comparison found ABC and formalin nearly equivalent. A 20% rectal ulcer rate has been reported but these are asymptomatic/self-resolving. ABC's main limitation is equipment/training availability rather than efficacy.
  • Other endoscopic modalities (bipolar electrocoagulation, Nd:YAG laser, radiofrequency ablation, cryotherapy) have far less supporting data; Nd:YAG's deeper/more variable penetration (~5mm) carries higher perforation risk.
  • Endoscopic dilation for radiation strictures — reported effective despite these strictures being notably firm/non-compliant; distal strictures can be dilated with Hegar dilators.

Surgery — last resort, reserved for refractory bleeding, obstructing strictures, fistulas, or disabling symptoms. Historically very high morbidity/mortality: a 1985 French series (85 patients) found 33% mortality and 30% enterocutaneous fistula rate after laparotomy for radiation injury (likely reflecting selection bias toward the most complicated patients); a Mayo Clinic series (1950–1983) found 80% complication and 14% mortality rates. Rectovaginal fistula resection success is particularly limited (Zelga: resection possible in only 4% of patients) — diversion alone is often the only option, and even after resection, ostomy closure is frequently not achievable (Zhong: only 3 of 26 resection patients had their ostomy eventually closed). Diversion improves quality of life and incontinence/obstruction-related symptoms but does not reliably resolve bleeding, pain, mucous drainage, or tenesmus. Resection (when tissue permits) offers the chance to remove all active disease, but patients must be counseled that reconstruction is often infeasible and a permanent ostomy is common.

Microscopic colitis — chapter detail

Chronic, relapsing, non-bloody diarrheal condition with grossly normal colonic mucosa but characteristic histologic abnormalities — diagnosis requires colonoscopy with biopsy and a high index of suspicion given nonspecific symptoms. Two subtypes distinguished only histologically: collagenous colitis (CC) — subepithelial collagen band ≥10 μm — and lymphocytic colitis (LC) — increased surface intraepithelial lymphocytes, collagen band <10 μm or absent. Same presentation and management for both; debate remains over whether they are one entity or two.

Epidemiology: incidence has risen substantially — Minnesota data went from 3.1/100,000 (CC) and 5.5/100,000 (LC) in the late 1980s to 19.6/100,000 combined by 2001; European data show a similar rise (1.1→5.2/100,000 across the 1990s); some recent estimates as high as 219/100,000 — unclear how much reflects true incidence rise vs. increased awareness/diagnosis. Mean age at diagnosis 61 (increasing incidence with age); female predominance (OR 2–8) suggesting hormonal/genetic contribution. Strong autoimmune-disease association — 40% of MC patients have another autoimmune disorder (type 1 diabetes, autoimmune thyroiditis, polyarteritis [OR 20.8 for CC, 8 for LC]); 40% of celiac disease patients also show MC-consistent histologic changes.

Risk factors: no direct genetic link identified but familial clustering observed; HLA/TNF-alpha gene polymorphisms implicated. Prior Yersinia enterocolitica infection and prior C. difficile infection both associated — consistent with an outside-antigen-plus-genetic-predisposition model, though causation unproven. Smoking: associated with increased incidence and earlier age at diagnosis (2013 study, 248 patients: OR 2.4 for CC, 3.8 for LC); smoking cessation is recommended though not proven to induce remission. Medications: NSAIDs (OR 3.8 CC / 4.7 LC), PPIs (OR 6.4 CC / 2.7 LC), SSRIs, statins all associated, though a large Pennsylvania database study failed to replicate a medication-CDI-type correlation — diarrhea-as-drug-side-effect prompting incidental colonoscopic diagnosis is one proposed confounding explanation. Cessation of suspect medications is still a reasonable initial management step.

Course: 75% achieve remission (no symptoms off medication for 1 year); spontaneous remission associates with more durable remission than drug-induced remission. Generally benign — does not increase colorectal cancer risk and may actually decrease colorectal adenoma incidence; serious complications (spontaneous or colonoscopy-associated perforation) are rare.

Diagnosis (Spanish Microscopic Colitis Group criteria): chronic/intermittent non-bloody diarrhea + macroscopically normal/near-normal colonoscopy + characteristic histopathology on biopsy. 10–15% of patients undergoing colonoscopy with appropriate biopsies for consistent symptoms are found to have MC. Full colonoscopy (not flexible sigmoidoscopy) with 2 biopsies per segment throughout the colon is mandatory — sampling only rectum/sigmoid reduces sensitivity since characteristic changes may not be present throughout. Fecal calprotectin is nonspecifically elevated (one study: 175 μg/g in MC vs. 28 in controls) — not useful for diagnosis or monitoring.

Treatment ladder: anti-diarrheals (loperamide/diphenoxylate) control symptoms without inducing remission; probiotics show no benefit over placebo. Bismuth salicylate has small-study support (one double-blind RCT: 100% response vs. 0% placebo in 14 patients; meta-analysis: 81% response rate). Antibiotic data (metronidazole, erythromycin, penicillin) is too limited to recommend. Budesonide is the evidence-based mainstay: Miehlke's double-blind RCT (57 patients) found 68% success vs. 21% placebo and 26% mesalamine; Münch treated 110 patients with 84% induction success, then randomized responders to budesonide 4.5mg/day maintenance vs. placebo — 61% remained in remission at 1 year vs. 16% on placebo. Recurrence after stopping budesonide is common, but it can be restarted successfully. Prednisolone can also induce remission (Munck: moderate response at 2 weeks) but at greater steroid-side-effect cost without superiority over budesonide, so it is not favored. Immunomodulators (6-MP, azathioprine, anti-TNF) have only small-study/case-report support and are reserved for rare severe, budesonide-refractory disease given MC's generally benign course. Surgery is not part of the standard algorithm but diversion (with or without resection) can be used for life-disabling, medically refractory disease — improves symptoms and decreases biopsy-proven inflammation (collagen band shrinks after diversion in CC), but symptoms recur if the ostomy is reversed. Two case reports describe IPAA for this indication with acceptable results, though there is no data supporting this as a standard strategy.

Ischemic colitis — chapter detail

Table 53.2 (mesenteric ischemia vs. ischemic colitis) formalizes the distinction already present in the wiki: mesenteric ischemia is a vascular accident (embolic/thrombotic/dissection) causing sudden onset, total blood-supply loss to the affected segment, pain out of proportion to exam, and requires emergent surgery; ischemic colitis is multifactorial, evolves over hours, causes transient (not total) ischemia with moderate pain/tenderness and hematochezia, and is usually managed medically. Anatomy: marginal artery of Drummond (collateral chain fed by terminal branches of each colic artery) is critical during low-flow states; splanchnic vessels receive 10–35% of cardiac output depending on physiologic state. Watershed regions (Griffith's area at the splenic flexure, Sudeck's point at the rectosigmoid junction) are most vulnerable when the marginal artery is not intact.

Epidemiology: general population rate 4–9/100,000 (Higgins review), but COPD patients have rates as high as 100/100,000 (RR 2.6–4.3). AAA repair association: a 110,000-patient review found IC rates of 0–4.6% after elective repair vs. up to 21% after emergency repair of a ruptured AAA.

Clinical presentation: IC is a major cause of lower GI bleeding — Newman found it responsible for nearly 20% of LGIB cases (second only to diverticulosis); Hreinsson's Icelandic population study found ~15% of acute LGIB was IC-related. Right-sided colitis less likely to present with rectal bleeding — isolated right-sided abdominal pain should keep IC on the differential.

Diagnosis: CT accuracy for bowel ischemia 74–79% depending on protocol/radiologist experience; Iacobellis's review of 130 patients undergoing CT for suspected IC found 100% had a CT finding consistent with the diagnosis (most commonly pericolonic/free fluid, bowel wall density changes, wall thickening) — though pneumatosis itself was present in <5% of acute-phase studies. When pneumatosis and bowel wall necrosis do coexist, mortality exceeds 70%. Colonoscopic findings by frequency: erythema (84%), edema (70%), superficial ulceration (57%), friability (43%), deep ulceration (22%), stenosis (8%), intraluminal blood (8%). The pathognomonic histologic finding is "ghost cells" — along with preserved crypt architecture with superficial crypt necrosis, mucin depletion, and a pseudomembrane-like sloughed-mucosa appearance.

Management: conservative therapy (bowel rest, IV hydration, broad-spectrum antibiotics covering anaerobic coliforms) for most patients without perforation/toxicity signs — antibiotics haven't been proven to alter disease course but are thought beneficial given increased mucosal permeability/ bacterial translocation and animal-model evidence of reduced bowel damage. Anticoagulation is not routinely recommended (IC is a microvascular/low-flow process, not typically a thrombotic one). Improvement should occur within hours to days; lack of improvement suggests progression toward transmural ischemia. Elective colonoscopy after resolution assesses healing/stricture; ~10% of initial responders later develop obstructive symptoms from a stricture, and another 20–30% develop chronic colitis from irreversible ischemic injury (persistent diarrhea/bleeding/weight loss) — both may warrant elective surgery. Emergent surgery for transmural ischemia/perforation signs (peritonitis, instability, free air, portal venous gas). Surgical mortality is substantial: Scharff's series found operative mortality as high as 40%. Anatomic resection (normal bowel to normal bowel) is preferred; primary anastomosis is generally avoided in the acute setting.

Open items / gaps

  • Radiation colitis, microscopic colitis, and ischemic colitis content above is all textbook-level/secondary, but the chapter is genuinely trial-rich — six named studies stand out as worth independently ingesting: Miehlke and Münch (budesonide RCTs for microscopic colitis), the Spanish Microscopic Colitis Group (Fernandez-Banares) consensus statement (source of the MC diagnostic criteria now in the wiki), Higgins (IC epidemiology review), Iacobellis (CT diagnostic-accuracy study for IC), and Scharff (IC surgical-outcome study). Flagged in Research Priorities.md.
  • 105 references total; only the load-bearing ones above are flagged — formalin/ABC administration technique series, prevention-agent studies, and mechanistic microscopic-colitis literature are treated as background detail already captured in the condition pages' narrative.